Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 1998

View Archived Issues

Company Profile: LXR Biotechnology

Cel-Sci's AIDS vaccine trial expanded to include The Netherlands

Novopharm Biotech's NOVOMAb-G2 IgM completes phase I

Integra LifeSciences to begin phase II clinical trials for Peripheral Nerve Regeneration Conduit

ZD-1839, an EGFR-TK inhibitor worthy of further testing

Rhone-Poulenc Rorer and IRORI enter combinatorial chemistry strategic alliance

Enzon allowed patent on its PEG technology

Ribozyme forms new target validation company

Astra and Merck & Co. restructure joint venture

Wyeth-Ayerst and ArQule sign five-year drug discovery collaboration

Hemosol awarded grant for Hemolink development

SB-RA-131012, an MDR-reversing taxane

Montelukast now available in Spain

Lilly expands women's health pipeline

PKC inhibitors for inflammatory/immune disorders developed at Astra

BioChem Pharma describes lactams for thrombotic disorders

Immunosuppressive, antiinflammatory and antitumor rapamycin derivatives

New cell adhesion inhibitors from Chiroscience

Another European market introduction for mizolastine

Czech investigators describe novel CDK inhibitor with potent antitumor activity

IL-2 fusion protein produces remission in late-stage refractory CTCL

Clozapine therapy results in increased leptin levels

YPE-01: a new diarylheptanoid effective against dermal inflammation

AxyS and Roche Bioscience embark on functional genomics collaboration

Nyotran compared to free nystatin and amphotericin B formulations in vitro

Controlled study refutes evidence indicating that garlic lowers lipids

Lilly presents results of first clinical trial evaluating the MDR modulator LY-335979

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...